Fulvic Acid Supplementation and Metabolic Syndrome

November 5, 2026 updated by: Carol Johnston, Arizona State University

Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome

Fulvic acid is a naturally occurring compound derived from the decomposition of organic matter in soil over long periods. Fulvic acid complexes, such as MLG-50 (MLG-50® Mineral Logic, Kalamazoo, Michigan), offer a highly concentrated, water-soluble form of fulvic acid that contains over 70 trace minerals and elements. Our preclinical studies have found that a soil derived organic mineral complex rich in fulvic acid prevented the high fat diet induced hyperglycemia, endothelial dysfunction, liver injury, endotoxemia, and gut dysbiosis induced by high-fat feeding in rats. We propose to examine the efficacy of fulvic acid (both 50 mg and 100 mg daily for 12 weeks) in the mitigation of symptoms related to metabolic syndrome.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Clinical trials examining the efficacy of fulvic acid on health parameters are scarce. However, shilajit, a natural substance rich in fulvic acid, was shown to reduce triglycerides, cholesterol, and increase HDL cholesterol as well as antioxidant status in healthy college students (n=30) after 45 days of supplementation (2 g daily). However, this quasi-experimental trial did not randomize participants into experimental groups, and causality cannot be evaluated. A 2018 review of the peer-reviewed literature on the therapeutic potential of fulvic acid concluded that although the available research is minimal, there was 'substantial evidence' to pursue fulvic acid research for improving biomarkers linked to chronic inflammatory diseases.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • metabolic syndrome or prediabetes

Exclusion Criteria:

  • pregnant or nursing
  • multiple medications to treat obesity, heart disease, thyroid conditions, cancer
  • smokers
  • competing athletes
  • vegetarians

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fulvic acid 50

50 mg
Dietary supplement: fulvic acid

50 mg

Dietary supplement: fulvic acid

100 mg
Experimental: Fulvic acid 100

100 mg
Dietary supplement: fulvic acid

50 mg

Dietary supplement: fulvic acid

100 mg
Placebo Comparator: Placebo

cornstarch
Other: Placebo

cornstarch

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
girth
Time Frame: from enrollment to 6 week and to 12 week

waist circumference in cm
from enrollment to 6 week and to 12 week
hypertension
Time Frame: from enrollment to 6 week and to 12 week

diastolic and systolic blood pressure
from enrollment to 6 week and to 12 week
hyperglycemia
Time Frame: from enrollment to 6 week and to 12 week

fasting blood glucose
from enrollment to 6 week and to 12 week
hypertriglyceridemia
Time Frame: from enrollment to 6 week and to 12 week

fasting blood triglycerides
from enrollment to 6 week and to 12 week
cholesterol
Time Frame: from enrollment to 6 week and to 12 week

fasting blood HDL cholesterol
from enrollment to 6 week and to 12 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Arizona State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 6, 2026

Primary Completion (Estimated)

November 15, 2027

Study Completion (Estimated)

November 15, 2027

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 5, 2026

First Posted (Actual)

November 10, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00024356

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no IPD.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe